Irish-listed speciality drug firm Amryt Pharma has agreed a €20m loan facility from the European Investment Bank, which will provide it with near- and mid-term funding requirements for its lead product, Episalvan.

Shares in Irish-listed speciality drug firm Amryt Pharma rose by 4% yesterday on the back of the company gaining orphan drug designation in the US for one of its compounds.

Amryt Pharma has been granted a US patent for its lead drug to be used as a treatment in the lucrative orphan disease market.